Sign in
Taking people in United StatesPhase 2

Immunotherapy drugs for melanoma that has spread to the brain

Tests relatlimab, nivolumab and ipilimumab in people with melanoma brain metastases.

Key facts

Who runs it
Stanford University
Where
Palo Alto, United StatesSee the site
Trial code
Registry title
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Status
Recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
6 Aug 2025
Expected to end
Feb 2030
Type of study
Interventional, 2 groups
Treatments tested
  • Ipilimumab
  • Nivolumab + Relatlimab FDC
Record updated
18 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with melanoma (not of the eye) that has spread to the brain, with or without symptoms. It tests relatlimab, nivolumab and ipilimumab.

Age
18 years or older
Sex
All sexes
Disease stage
Non-uveal melanoma that has spread to the brain, with at least 1 measurable brain lesion of 5-40mm not treated before with local therapy. Cohort A has no brain symptoms (ECOG 0-1). Cohort B has brain symptoms (ECOG 0-2).
Earlier treatment
No earlier anti-CTLA-4, anti-PD-1 or anti-LAG-3 treatment for unresectable stage III/IV melanoma. Such treatment before or after surgery is fine if more than 6 months ago. Earlier BRAF+MEK inhibitors are fine if more than 2 weeks ago. No prior whole brain radiation.
Biomarker or test result
A tumor tissue sample is needed to test PD-L1. If no sample exists and a new biopsy is not possible, the person may still join.

Main reasons for not taking part

  • Another primary cancer in the past 3 years (with some exceptions)
  • Spread to the membranes around the brain and spinal cord (leptomeningeal metastasis)
  • Active autoimmune disease treated with steroids or immune-suppressing drugs in the past 3 years
  • Serious heart disease or raised troponin levels
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Histologically confirmed non-uveal melanoma that has metastasized to the brain. At least 1 measurable intracranial target lesion (5-40mm) which was not previously treated with local therapy (no prior SRS to this lesion). Prior surgery for a brain metastasis is allowed but this lesion cannot be a target lesion; Growth or change in a lesion previously irradiated will not be considered measurable. Regrowth in cavity of previously excised lesion will not be considered measurable
  • Age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1 for Cohort A (asymptomatic), ECOG performance status 0-2 for Cohort B (symptomatic)
  • No prior anti-CTLA-4, anti-PD-1, or anti-LAG-3 therapy for unresectable stage III/IV melanoma. Prior CTLA-4, PD-1, and/or LAG-3 therapy in the neoadjuvant or adjuvant setting is acceptable if >6 months since last treatment. Participants may have had prior BRAF+MEK inhibitors for adjuvant therapy and/or unresectable/metastatic melanoma if >2 weeks have elapsed since last treatment
  • Adequate organ function as assessed by the following parameters:; Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal (≤ 3 ×ULN); patients with liver metastasis ≤ 5 × ULN; Estimated creatinine clearance (eCrCl) ≥ 30 mL/min using the Cockcroft-Gault formula at Screening; Total bilirubin ≤ 1.5x ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels >1.5x ULN
  • Patients must have recovered from all prior anti-cancer therapy-related adverse events (AEs) to ≤ Grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE] v 5.0), except for alopecia, vitiligo, thyroid dysfunction, hypophysitis, or adrenal insufficiency, prior to enrollment
  • Cohort A (asymptomatic): participants must be free of neurologic signs and symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroid therapy greater than physiologic replacement (>10 mg of prednisone/day or equivalent) in the 10 days prior to beginning protocol therapy. Cohort B (symptomatic): participants may be on steroids with doses no higher than a total daily dose of 4 mg of dexamethasone or equivalent that is stable or tapering within 10 days prior to treatment. Patients who are symptomatic and are not being treated with steroids are also eligible
  • Participants with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 90 days prior to treatment
  • Participants with a known history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection must have been treated and cured. Participants with HBV or HCV infection who are currently on treatment must have an undetectable HCV viral load prior to treatment
  • Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (blocks are preferred) OR at least 4 unstained slides, with an associated pathology report, for testing of tumor PD-L1 expression:; Tumor tissue should be of good quality based on total and viable tumor content; Patients who do not have tissue specimens may undergo a biopsy during the screening period. Acceptable samples include core-needle biopsies for deep tumor tissue or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions. Fine Needle Aspirations (FNA) will not be considered acceptable for tissue procurement; Tumor tissue from bone metastases is not evaluable for PD-L1 expression and is therefore not acceptable; However, if repeat biopsy is not feasible, and no archival tissue available patient still may be enrolled
  • Any radiation treatment or excision of non-target brain lesions must have occurred ≥ 1 weeks before the start of dosing for this study. NOTE: The radiation field must not have included the brain index lesion(s)
  • Radiation to non-CNS lesions is allowed and does not require a washout period for treatment initiation. Any radiation-related toxicity must have recovered to ≤ Grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE] v 5.0)
  • Women of child-bearing potential (WOCBP) must not be breastfeeding and must have a negative pregnancy test within 3 days prior to initiation of dosing. WOCBP (or female partners of male participants) must agree to use an acceptable method of birth control from the time of the negative pregnancy test, through the duration of treatment with the study combination and for 12 months after their last dose of any study component medication; NOTE: A female participant is eligible to participate if she is not a woman of childbearing potential; Approved methods of birth control are as follows:; Combined (estrogen and progesterone containing) hormonal birth control associated with inhibition of ovulation: oral, intravaginal, transdermal Progesterone-only hormonal birth control associated with inhibition of ovulation: oral, injectable, implantable Intrauterine device (IUD) Intrauterine hormone-releasing system (IUS) Bilateral tubal occlusion Vasectomized partner True sexual abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar ovulation, symptothermal, post-ovulation methods) is not acceptable
  • Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an ICF approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC) and agree to abide by the study restrictions and return to the site for the required assessments

Who cannot take part

  • Another primary malignancy within the previous 3 years (with the exception of carcinoma in situ of the breast, cervix, or bladder; localized prostate cancer; and non-melanoma skin cancer that has been adequately treated)
  • Prior Grade 4 treatment-related AE with immune checkpoint inhibitor treatment
  • Prior whole brain radiation therapy (WBRT)
  • Investigational drug use within 14 days (or 5 half-lives, whichever is longer) of the first dose of study treatment
  • Dexamethasone use > 4mg/day (or equivalent)
  • Active medical illness(es) that would pose increased risk for study participation, including: active systemic infections (including COVID-19), coagulation disorders, or other major active medical illnesses of the cardiovascular, respiratory, or immune systems
  • Active autoimmune disease that has required systemic therapy with corticosteroids or other immunosuppressive agents within the past 3 years (excluding immune-related adverse events from immunotherapy as described above
  • History of leptomeningeal metastasis determined by imaging or lumbar puncture
  • History of clinically significant cardiac disease or congestive heart failure > New York Heart Association (NYHA) class 2. Subjects must not have unstable angina (anginal symptoms at rest) or new-onset angina within the last 3 months or myocardial infarction within the past 6 months or a history of myocarditis
  • Troponin T (TnT) or I (TnI) > 2 × institutional ULN. Participants with TnT or TnI levels between > 1 to 2 × ULN will be permitted if repeat levels within 24 hours are ≤ 1 ULN. If TnT or TnI levels are between >1 to 2 × ULN within 24 hours, the participant may undergo a cardiac consultation and be considered for treatment, following cardiologist recommendation. When repeat levels within 24 hours are not available, a repeat test should be conducted as soon as possible. If TnT or TnI repeat levels beyond 24 hours are < 2 × ULN, the participant may undergo a cardiac consultation and be considered for treatment, following cardiologist recommendation. Notification of the decision to enroll the participant following cardiologist recommendation has to be made to the principal investigator
  • Implanted device that precludes the use of MRI
  • Women who are breast-feeding or pregnant

Where in United States

  • Stanford UniversityPalo Alto, United StatesContact: Divya Divya PathakTaking people

About the trial

What the trial wants to find out

This is a multicenter, phase II trial of relatlimab (rela), nivolumab (nivo), and ipilimumab (ipi) in patients with asymptomatic and symptomatic melanoma brain metastases.

The 2 groups in the trial

  • Cohort A: AsymptomaticTreatment being tested

    Treatment: Ipilimumab and Nivolumab + Relatlimab FDC

  • Cohort B: SymptomaticTreatment being tested

    Treatment: Ipilimumab and Nivolumab + Relatlimab FDC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Multicenter, Phase II Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Plain-language title
Immunotherapy drugs for melanoma that has spread to the brainGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
18 May 2026